Digital Health Investment

investing in

We are the strategic investment fund of Debiopharm

Investment focus is Smart Data & Digital Health in oncology and infectious disease, with an impact on drug development and the patient journey

Company stage
Late pilot or early commercial
Investment round
Series A and B
Our initial investment
$1M - 10M
Startup funding
Our latest portfolio news
June 17, 2020

Immunexpress awarded funding to develop their COVID-19 patient triage test SeptiCyte® RAPID

Read more
May 26, 2020

Acquisition of Kaiku Health by the swedish company Elekta

Read more
See all news


Discover our Portfolio

Our current and past investments


At a glance

Our mission

Our objective is to make strategic investments in innovative companies with technologies and business models that change the way we develop drugs and treat patients.

We bring value to our portfolio companies through our knowledge in medicine, pharmaceutical development, regulatory/reimbursement aspects, management and expertise in bringing products to market. We drive our portfolio investments to successful exits.

Our objectives

  • 2-3 new investments per year
  • Active involvement to help portfolio companies develop
  • Long term value creation

Our investment criteria

  • Strong management team
  • Ambitious vision
  • Innovative technology
  • Robust execution plan


  • Over 100 million invested since 2008
  • Cumulative equity raised by all companies: USD 500 million
  • We led 12 out of the 15 last investment rounds
  • Portfolio company achievements: 18 FDA clearances or CE marks, 2 IPOs
Leadership team

Discover the people who guide and bring long-term vision to the digital health investments at Debiopharm

Leadership Team
Startup funding

Are you a startup looking for funding? Discover our criteria investment in Smart Data & Digital Health